Tufts Clinical and Translational Science Institute

塔夫茨临床与转化科学研究所

• 批准号: 10412102
• 负责人: Harry P. Selker
• 金额: $ 966.99万
• 依托单位: TUFTS UNIVERSITY BOSTON
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10412102
• 关键词: Caring; Clinical Research; Clinical Sciences; Collaborations; Development; Discipline; Education; Environment; Evaluation; Growth; Health; Health Policy; Healthcare; Institutes; Leadership; Longevity; Mentors; Mentorship; Methods; Multi-Institutional Clinical Trial; National Center for Advancing Translational Sciences; New England; Participant; Performance; Population Heterogeneity; Process; Public Health; Reflex action; Research; Research Methodology; Research Support; Resource Sharing; Resources; Role; Science; Services; System; Training and Education; Translational Research; Translations; Vision; Work; base; care delivery; clinical practice; improved; innovation; novel; programs; skills; translational pipeline

Over its 10 years, Tufts Clinical and Translational Science Institute (CTSI) has brought together purposefully-selected partners and has organized new and existing programs and activities with a singular purpose to best contribute to clinical and translational research (CTR). We focus on what we are best suited to do, based on our particular skills, resources, partners, and opportunities. Thereby, we have been able to provide unique and outstanding services, resources, education, and mentorship, locally, nationally, and to the field of CTR. With this application, we are pleased to be able to substantially grow our offerings by expanding our long-standing partners’ contributions, and by adding the special assets of new partners. With growth, our guiding principles have not changed: 1) We actively support the full spectrum of translational research, and we insist that wherever on the T1-T4 continuum, CTR must have a clear line of sight to potential ultimate impact on health; 2) At all stages of research, we practice “broadly-engaged team science.” For CTR to be relevant and impactful, research teams must have a wide array of stakeholders from inception to completion and dissemination; 3) We are active collaborators. We embrace our role as “the extrovert CTSA.” We believe that connections among diverse disciplines, stakeholders, and organizations are synergistic on many levels. This has powered our hub, and our leadership of multiple CTSA Consortium activities; 4) We believe that only by having systems and processes to continually assess and to iteratively improve processes will we achieve CTR excellence. We have a signature program in research process improvement, which we apply across CTR, and which led to our leading the national roll-out of the CTSA Common Metrics; 5) We reflexively look for opportunities to contribute novel research methods. Development, demonstration, and dissemination of new methods and approaches are hallmarks of our work, regardless of domain; 6) Rigorous role-specific education and training are fundamental to excellence in, and advancing, CTR. In service of these principles, our aims are: Overall AIM 1) Create an environment, resources, and services to stimulate and support the full spectrum of CTR by leveraging the diverse expertise and assets of Tufts CTSI partners. Overall AIM 2) Cultivate broadly-engaged team science, actively including stakeholders, to promote relevant and impactful translation for diverse populations and across the lifespan. Overall AIM 3) Develop, demonstrate, and disseminate innovations in methods, research process improvement, and evaluation, to advance CTR locally and nationally. Overall AIM 4) Advance methods and performance of multi-site clinical trials, within the Tufts CTSI Clinical Research Network, the NCATS Trial Innovation Network, and in other multi-institutional networks. Overall AIM 5) Provide outstanding education, training, and mentoring, tailored to different roles and disciplines, to advance a diverse CTR workforce, and share these resources nationally.

塔夫茨临床和转化科学学院（CTSI）在10年中，已经汇集了 有目的选择的合作伙伴，并以奇异的方式组织了新的和现有的计划和活动 最佳促进临床和翻译研究（CTR）的目的。我们专注于最适合的 根据我们的特定技能，资源，合作伙伴和机会。因此，我们已经能够 在本地，全国范围内提供独特而杰出的服务，资源，教育和心态，并向 CTR领域通过此应用程序，我们很高兴能够通过扩展来实质性地发展我们的产品 我们长期存在的合作伙伴的贡献，并增加了新合作伙伴的特殊资产。 随着增长，我们的指导原则没有改变：1）我们积极支持全面的翻译 研究，我们坚持认为，无论在T1-T4连续体上，CTR都必须具有清晰的视线至潜力 对健康的最终影响； 2）在研究的各个阶段，我们实践“广泛参与的团队科学”。对于CTR 要具有相关性和影响力，研究团队必须从成立到 完成和传播； 3）我们是积极的合作者。我们将自己的角色作为“性格外向的CTSA”。 我们认为，潜水员学科，利益相关者和组织之间的联系是协同的 许多级别。这为我们的枢纽提供了动力，以及我们对多个CTSA财团活动的领导。 4）我们 相信只有通过具有连续评估和迭代改进流程的系统和流程 我们会取得卓越的CTR。我们在研究过程改进方面有一个签名计划，我们 遍及CTR，这导致了我们领先的国家推出CTSA普通指标； 5）我们 反身寻找机会来贡献新颖的研究方法。开发，演示和 无论领域如何，新方法和方法的传播都是我们工作的标志。 6）严格 特定角色的教育和培训是CTR的卓越和前进的基础。 为了服务这些原则，我们的目标是：总体目标1）创建一个环境，资源和服务 通过利用潜水员的专业知识和Tufts CTSI的资产来刺激和支持CTR的全部范围 合作伙伴。总体目标2）培养广泛参与的团队科学，包括利益相关者在内，以促进 对潜水员人群和整个寿命的相关和有影响力的翻译。总体目标3）发展， 在方法，研究过程改进和评估中证明并传播创新 在本地和全国范围内提高CTR。总体目的4）多站点临床的提前方法和性能 试验，在Tufts CTSI临床研究网络，NCATS试验创新网络中以及其他试验中 多机构网络。总体目标5）量身定制的出色的教育，培训和心理 不同的角色和学科，以促进潜水员CTR劳动力，并在全国范围内共享这些资源。

项目成果

Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.

• DOI: 10.1001/jamanetworkopen.2021.44942
• 发表时间: 2022-02-01
• 期刊: JAMA network open
• 影响因子: 13.8
• 作者: Cairns DM;Dulko D;Griffiths JK;Golan Y;Cohen T;Trinquart L;Price LL;Beaulac KR;Selker HP
• 通讯作者: Selker HP

Neonatal abstinence syndrome practice variations across pediatric subspecialty.

• DOI: 10.1038/s41372-020-00831-8
• 发表时间: 2021-06
• 期刊: Journal of perinatology : official journal of the California Perinatal Association
• 作者: Yen E;Murphy HJ;Friedman H;Lucke AM;Rodday AM
• 通讯作者: Rodday AM

Readmission following surgical stabilization of rib fractures: Analysis of incidence, cost, and risk factors using the Nationwide Readmissions Database.

• DOI: 10.1097/ta.0000000000003227
• 发表时间: 2021-08-01
• 期刊: The journal of trauma and acute care surgery
• 作者: Aalberg JJ;Johnson BP;Hojman HM;Rattan R;Arabian S;Mahoney EJ;Bugaev N
• 通讯作者: Bugaev N

Decision-Making Engagement Preferences among Older Adults with CKD.

患有 CKD 的老年人的决策参与偏好。

• DOI: 10.1681/asn.0000000000000341
• 发表时间: 2024
• 期刊: Journal of the American Society of Nephrology : JASN
• 作者: Gonzales,KristinaM;Koch-Weser,Susan;Kennefick,Kristen;Lynch,Mary;Porteny,Thalia;Tighiouart,Hocine;Wong,JohnB;Isakova,Tamara;Rifkin,DenaE;Gordon,ElisaJ;Rossi,Ana;Weiner,DanielE;Ladin,Keren
• 通讯作者: Ladin,Keren

Community Member and Health Care Provider Perspectives on Communication With Chinese American Patients With Cancer: A Qualitative Study.

社区成员和医疗保健提供者对与华裔美国癌症患者沟通的看法：一项定性研究。

• DOI: 10.1200/op.22.00047
• 发表时间: 2022
• 期刊: JCO oncology practice
• 影响因子: 4
• 作者: Robbel,Courtney;Vesel,Linda;Ernst,Emma;He,Yang;Vesel,Tamara
• 通讯作者: Vesel,Tamara